Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma

NCT00849654 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT00849654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00849654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose-Escalation Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2009
Completion date
July 31, 2012
Enrollment
66 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell leukemia, b-cell lymphoma